Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Wei G, Regenstein JM, Zhou P
Clinicians are well placed to discuss the current evidence base, explain what is and is not yet available, and help you access appropriate care through legitimate channels
BPC157 is not FDA-approved, but it is legal to buy for research purposes in many countries
The result is a peptide with a half-life of 159 to 195 hours, roughly 7 to 8 days, making once-weekly administration possible
600 mcg resM Postbiotic
Phase 3 TRIUMPH Program (Ongoing) - LIVER AS SECONDARY ENDPOINT Status: Currently ongoing, results expected 2026 TRIUMPH-4 (Completed December 2025): Primary endpoints: Weight loss + osteoarthritis pain Results: 28.7% weight loss at 68 weeks Liver outcomes: Secondary/exploratory endpoints TRIUMPH-2 (Ongoing, expected 2026): Weight loss in obesity + type 2 diabetes Liver outcomes: Secondary endpoints (liver enzymes, possibly imaging) Key Point: TRIUMPH Phase 3 trials are NOT primarily liver-focused
US$ 25.24
US$ 20.06
US$ 22.46
US$ 24.72
US$ 21.83
US$ 29.00
US$ 28.43
US$ 20.01
